Skip to main content

Table 2 Intra- versus intergroup comparison of variables at the baseline versus at 3 months follow-up among the two groups

From: Effect of carvedilol versus nebivolol on insulin resistance among non-diabetic, non-ischemic cardiomyopathy with heart failure

  G1 G2 Inter-group
Baseline After 3 months Baseline After 3 months cP dP
1. HR 102 ± 7 71 ± 5 103 ± 9 70 ± 6   
 Intragroup t test aP < 0.001* bP < 0.001* 0.68 0.55
2. BP 137 ± 7 130 ± 8 135 ± 6 130 ± 9   
85 ± 9 80 ± 10 32 ± 5 80 ± 6
 Intragroup t test aP < 0.001*, < 0.001* bP < 0.001*, < 0.02* 0.21 0.68
3. NYHA Class I 20 (80%) 19 (76 %) 12 (66.7%) 14 (77.8%)   
Class II 6 (24%) 6 (24%) 6 (33.3%) 4 (22.2%)
 Intragroup t test aP = 0.03* bP = 0.046* 0.85 0.99
4. EF% 39 ± 4.2 42 ± 3.0 38.9 ± 3.2 41.8 ± 3.3   
 Intragroup t test aP < 0.001* bP < 0.001* 0.93 0.84
5. B blocker compliance 24 (96%) 24 (96%) 17 (94%) 17 (94%)   
 Intragroup t test aP > 0.99 bP > 0.99 0.99 0.99
6. HbA1c 5.8 ± 0.8 5.9 ± 0.3 5.9 ± 0.6 5.3 ± 0.2   
 Intragroup t test aP = 0.76 bP < 0.001* 0.55 < 0.001*
7. Fasting glucose (mg/dl) 102 ± 14 103 ± 9 103 ± 9 97 ± 7   
 Intragroup t test aP = 0.73 bP < 0.001* 0.31 0.023*
8. Plasma insulin (lU/ml) 5.3 ± 3.2 5.4 ± 3.9 5.4 ± 4.1 3.5 ± 0.23   
 Intragroup t test aP = 0.62 bP = 0.01* 0.92 0.046*
9. HOMA-IR 1.31 ± 0.29 1.37 ± 0.3 1.37 ± 0.3 1.21 ± 0.08   
 Intragroup t test aP = 0.41 bP = 0.01* 0.52 0.01*
10. Plasma norepinephrine (pg/ml%) 530 ± 159 436 ± 30 531 ± 171 499 ± 102   
 Intragroup t test aP = 0.002* bP = 0.08 0.98 0.019*
11. Plasminogen activator I (ng/ml) 9.9 ± 3.2 9.8 ± 2.7 10.2 ± 2.5 10.1 ± 3.3   
 Intragroup t test aP = 0.37 bP = 0.81 0.74 0.75
  1. HR heart rate, BP blood pressure, HbA1c glycated hemoglobin, HOMA-IR homeostasis model of assessment, NYHA New York Heart Association Classification, EF ejection fraction, G1 group 1, G2 group 2
  2. *P is significant
  3. aP intragroup comparison of group 1
  4. bP intragroup comparison of group 2
  5. cP intragroup comparison of group 1; intergroup comparison of group 1 and group 2 at baseline
  6. dP intergroup comparison of group 1 and group 2 after 3 months